title: Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators.
abstract: Improving the delivery of oxygen to the tissues by decreasing the oxygen affinity of haemoglobin has been a major aim of several laboratories over recent years because this may reduce the consequences of anaemia and/or improve tissue oxygenation in cases of decreased blood perfusion. Within the same context, lowering the oxygen affinity may prove valuable in the application of native or recombinant haemoglobin solutions as a blood substitute. The shift of the oxygen equilibrium curve to the right is obtained by various modulators. Among them, the bezafibrate derivatives are considered as a most interesting group. These principles are of the utmost importance in thalassaemia and other haemoglobinopathies where the beneficial effects of the compensatory synthesis of fetal haemoglobin are diminished by the increased oxygen affinity of this pigment. In this paper we present the results of a study initiated to determine whether a potent oxygen affinity modifier, RSR-4, could satisfactorily decrease the oxygen affinity of fetal haemoglobin, thus improving tissue oxygenation. The experiments were carried out on whole blood and on purified haemoglobin solutions and showed that the effector markedly decreased the oxygen affinity of HbF (from 18.7 to 3.73 mmHg in whole blood). At the same time the cooperativity index (n50) and the oxygen saturation levels remained within normal limits under the conditions of the main experiment. These observations have important implications for the potential application of oxygen affinity modifiers in vivo.
authors.affiliation: Haematology Laboratory, Aghia Sophia Children's Hospital, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Papassotiriou
authors.forename: J
authors.initials: J
authors.lastname: Kister
authors.forename: N
authors.initials: N
authors.lastname: Griffon
authors.forename: A
authors.initials: A
authors.lastname: Stamoulakatou
authors.forename: D J
authors.initials: DJ
authors.lastname: Abraham
authors.forename: M C
authors.initials: MC
authors.lastname: Marden
authors.forename: D
authors.initials: D
authors.lastname: Loukopoulos
authors.forename: C
authors.initials: C
authors.lastname: Poyart
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology*; D002712:Chlorides / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005319:Fetal Hemoglobin / Q000378:metabolism*; D006801:Humans; D010100:Oxygen / Q000378:metabolism*; D010101:Oxygen Consumption; D011422:Propionates / Q000494:pharmacology*; D017086:beta-Thalassemia / Q000378:metabolism*
chemical_list: D000814:Aniline Compounds; D002712:Chlorides; D011422:Propionates; C077066:4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid); D005319:Fetal Hemoglobin; D010100:Oxygen